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Abstract
Pain is one of the most difficult medical problems to diagnose and treat and can be a common
symptom of several psychiatric disorders. Pain-related issues are heterogeneous and often
underestimated or misinterpreted, with the result that psychiatric interventions, which might have
been beneficial from the outset, are often delayed or requested only as a last measure. Several
problems arise from the definition, classification and assessment of pain, when documented
according to the different scales which are commonly used, since these attempt to cover a
multitude of analytical requirements, without really succeeding. An area of constant debate regards
the connection between pain and various psychiatric disorders, and the difficulty in the classification
of pain disorders within the currently existing framework. The pharmacological treatment of pain
is complex and implies a variety of different compounds, from opioids to psychotropic medications
like antidepressants and anticonvulsivants.
This paper explores the mutual and reciprocal influence between pain and psychiatric disorders
reviewing the latest developments in the definition, assessment and treatment of pain, with special
emphasis on the impact of pain on psychiatric disorders (and vice versa), and on the use of
psychotropic drugs in the treatment of pain syndromes.
Background
Pain: definition, epidemiology and classification
Pain is a complex experience which includes affective,
cognitive and behavioural features, all of which are the
result of mental processes and, as such, it represents a psy-
chological condition [1]. The phenomenon of pain, there-
fore, involves pathophysiological and psychological
components that are frequently difficult to interpret. Suf-
fering is a term frequently used in conjunction with pain,
implying the conscious endurance of pain or distress and
refering to a wide range of intense and unpleasant subjec-
tive states that may be of physical or psychologic origin.
The most comprehensive and exhaustive definition of
pain is the one provided by the International Association
for the Study of Pain, namely "an unpleasant sensation
and an emotional experience associated with a real or
potential damage to tissue, or the equivalent of such dam-
age"[2]. This definition attempts to overcome the dualism
between pain provoked by an evident organic disease and
that related to psychological factors, that is, between
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the patient's suffering is real.
Pain is a common problem in the general population and
is one of the most frequent factors leading patients to con-
sult a physician [3,4]. When patients suffer from chronic
pain – defined as daily pain which has persisted beyond a
month or beyond what would normally be considered the
appropriate time for recovery from the underlying pathol-
ogy in question – various specialists are involved in their
treatment, but they rarely include a psychiatrist [5-11].
The U.S. Centre for Health Statistics carried out an 8-year
follow-up study, which showed that 32.8% of the U.S.
civilian population suffered from symptoms related to
chronic pain [12]. A recent study carried out by the World
Health Organization, which involved more than 25.000
patients in 14 different countries, reported that the 22% of
primary care patients had suffered from pain which had
been present for most of the time throughout a period of
at least 6 months [13]. A review of elderly populations
[14,15] shows that the percentage of individuals affected
by some kind of pain rises to 50%, and that this is associ-
ated with a significant impairment of social functioning
and quality of life; furthermore, about one third of
chronic pain cases in elderly people are not recognized by
their caregivers [16-19].
In spite of its relevance, pain has long been neglected by
the past editions of the Diagnostic and Statistical Manual
of Mental Disorders (DSM).
Pain "determined" by emotional factors had been classi-
fied within the DSM-II amongst psychophysiological dis-
orders [20]. The DSM-III coped with the problem of
chronic pain while introducing the concept of psycho-
genic pain disorder, where the pathophysiological aspects
were absent or insufficient to explain the length and the
severity of pain [21]. For somatoform pain disorder
(DSM-III), psychological factors were no longer required
in pain etiology [22].
In the revision of the third edition of the DSM-III (DSM-
IIIR), specifications requiring psychological factors to be
present, and that the pain should not be due to another
mental disorder, were deleted and, instead of considering
pain itself, the presence of "pain related problems of at
least 6 months' duration" was introduced as the main cri-
terion. In line with these changes, the disorder was
defined as "somatoform pain disorder". The literature
available indicates that the categories of disorders charac-
terized by pain in DSM-III and DSM-IIIR were rarely used
for the diagnosis of patients affected by pain [23]. The evi-
dent limitations of the diagnosis of psychogenic and
somatoform pain led to the introduction of a new diag-
nostic group more widely defined in the DSM-IV as "pain
disorder".
The DSM-IV introduced this category to better define the
diagnostic subgroup of somatoform disorders present in
the DSM-III-R, which includes also conversion disorder,
hysteria and body dysmorphic disorder, all characterized
by the common feature of the presence of a physical
symptom, which is suggestive of a medical disorder but
has not been provoked by it or by substance use [24,25].
Primary criteria for the diagnosis of pain disorder include
1) pain as the main problem and 2) pain determining sig-
nificant stress or functional impairment. This diagnosis
requires also that although psychological factors may play
an important role, the pain must not be the result of
another mental disorder, such as an anxiety disorder or
depression. Thus, if the presence of another mental disor-
der is determined, then a diagnosis of pain disorder is not
acceptable. Furthermore, it is required that the pain being
suffered be defined as acute or chronic and whether asso-
ciated only with psychological factors or with both psy-
chological factors and a general medical condition.
Therefore, the concept of psychological and physical dual-
ism is innate within such a diagnosis.
By definition, a specific medical cause underlying the var-
ious somatoform disorders is rarely present [26]; how-
ever, in parallel with the increase in "psychogenic"
symptoms, functional or social impairments may arise,
there may be an increase in medical treatments, inade-
quate therapeutic strategies or diagnostic examinations,
and psychiatric disorders may appear [26,27]. These
patients have a higher likelihood of reporting catastrophic
thoughts and they tend to think that the origin of their
pain is a mystery; they feel that they have lost control and
that their physicians do not believe their pain to be real.
Patients suffering from chronic pain and presenting symp-
toms with no medical explanation, suffer also from the
iatrogenic consequences of their symptoms, such as an
excessive number of medical evaluations and long-term
treatments with inadequate drugs [28]. Although the diag-
nosis of somatization disorder is rare in patients with
chronic pain, somatization is a common occurrence in
medical practice and it may arise with different degrees of
severity and be seen in several forms [29]. Somatization
may be conceptualized by three distinct, albeit overlap-
ping, models of behavior, according to which "symptoms
may be perceived, evaluated and managed differently by
different kinds of persons". These three forms include 1)
a high level of symptoms which cannot be explained by
physiological systems; 2) somatic pathology, related to
worries, which is more severe than would normally be
expected under the circumstances (as far as can be deter-
mined), and 3) the predominantly or exclusively somatic
presentation of symptoms of psychiatric disorders, such asPage 2 of 11
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such as the social stigma of psychiatric disorders, a history
of physical or sexual abuse and the medical attention
given to biochemical paradigms, predispose and reinforce
somatization [33-35].
Other classification systems have been proposed, but
none is widely applied: the most comprehensive is that
developed by the taxonomy sub-committee of the Inter-
national Association for the Study of Pain [2] which has
set up a model based on 5 axes. Psychological factors may
be indicated on both the second axis, where psychiatric
disorders may be codified within the central nervous sys-
tem, and on the fifth axis, where psychophysiological or
psychological etiologies may be included.
More controversial, however, is the nosological position
of chronic pain syndrome, which is not included any-
where, although this term is frequently used for those
individuals suffering from pain for long periods. Black's
definition [36], the most widely accepted, applies the fol-
lowing criteria: untreatable and often multiple areas of
pain, usually unrelated to any existing somatic problems,
previous contacts with various physicians and diagnostic
procedures, excessive worry related to the pain and altered
behavior including depressive, anxious or neurotic fea-
tures. However, the validity of this diagnosis is limited
because some of the above-mentioned criteria are highly
subjective and repeated diagnostic tests might have been
due to low awareness of the pain on the part of the physi-
cian. For these reasons, the diagnosis of chronic pain syn-
drome, according to some authors, should be avoided
[23].
Pathophysiology of pain
Different theories have been proposed in this field and,
although none is considered exhaustive, the most
accepted is the gate control hypothesis [37]. It postulates
that the transmission of nerve impulses from the periph-
ery through the central nervous system (CNS) is modu-
lated by T-cells in the substantia gelatinosa of the dorsal
horn of the spinal cord, which are influenced by different
inputs. These include large inhibitory and small facilitat-
ing fibres from the brain, the level of arousal via the retic-
ular activating system and autonomic modulation via the
sympathetic ganglia. This theory has considerable heuris-
tic merit and provides a rationale by which emotions or
experience could affect pain. A variety of biochemical
mechanisms also modulate pain. Analgesia is enhanced
by increased levels of serotonin in the periacqueductal
grey matter or by potentiating inhibitory substance P in
the spinal cord; the opposite may result from the blockade
of dopamine or increase of norepinephrine in the lateral
reticular formation. These mechanisms indicate the
potential effects of biogenic amines and psychotropic
drugs on pain, which probably have a modulating but less
specific function than brain opiate receptors and the
endogenous or exogenous substances acting at their level
in both the limbic system and the substantia gelatinosa
[38].
Assessment of pain
It is sometimes difficult to evaluate pain, especially in
patients with a terminal disease, with cognitive impair-
ments or other chronic degenerative neurological disor-
ders [9,10]. Different pain rating scales are available to
assess the severity and the intensity of pain, but several
factors may influence these evaluations, in particular the
somatic conditions, the co-occurrence of psychiatric dis-
orders, the presence of stress, the personality characteris-
tics and an interpretation based on subjective experience.
A complete evaluation should be carried out with every
patient suffering from pain or agitation or with an evident
worsening of his/her functional status. This evaluation
should take into consideration simple standardized items
to measure the severity of pain, the observation of any
pain-associated behavior such as difficulty with daily life
activities as a result of pain and a clinical examination in
order to localize the pain and any signs which might sug-
gest possible etiological agents.
Given that pain is a subjective experience, several methods
have been proposed for its evaluation and measurement
[39,40], although none has yet proven universally valid.
The simplest measurement of pain is the Numeral Evalua-
tion Scale, where the patient is asked to assign a number to
the pain suffered. The typical scale has a range of 0 to 10,
with "0" representing a total absence of pain and "10" the
worst imaginable pain. Strongly related to this is the vis-
ual analogical scale that requires the subject to indicate a
point along a line of 10 cm, where 0 is no pain and 10 is
the worst [41].
The McGill Pain Questionnaire offers a more accurate anal-
ysis [42], with the test listing 20 series of words describing
the pain and assigned to sensorial, affective and rating
scales. The test score may be defined on the basis of the
total number of words chosen or by the order in which
they are expressed. Some studies, however, indicate that
the modality of response varies according to the kind of
pain [43]; the McGill Pain Questionnaire has been criti-
cized because it is based excessively on linguistic abilities,
and consequently, its results may be influenced by the
degree of individual intelligence or education.
An alternative test commonly used is the West Heaven-Yale
Multidimentional Inventory, composed of 52 items which
measure the way in which patients perceive other people'sPage 3 of 11
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the effect that the pain is having on their global lifestyle
[44].
Other more traditional psychological evaluation tests
have also been used, such as the Minnesota Multiphasic Per-
sonality Inventory (MMPI); nevertheless, the validity of this
and other similar tests is controversial when applied to
subjects with pain. For instance, it has been reported that
more than 40 years ago, individuals with back pain whose
origin was not organic, were more likely to present a cer-
tain MMPI configuration, the so called "V of conversion"
or "neurotic triad", where it was believed that an increase
in hypochondria and hysteria scale reflected patients' wor-
ries about their own health [45], while a lower score of
depression indicated that the patient was indifferent to
such worries. Despite the existence of supporting data,
other studies would suggest that this specific configura-
tion may represent a sort of adaptation to a chronic disor-
der and, consequently, it may be a characteristic of
patients with chronic health problems, independently of
any identified organic etiology [46,47].
To assist caregivers in distinguishing whether a patient's
pain had an organic or a psychological origin, Waddel and
co-workers [48] suggested the noting of 5 possible signs:
1) pain which is superficial or without anatomic distribu-
tion; 2) pain which is induced by any movement which
should not be painful but which might appear similar to
some other movement which normally would be; 3) pain
which seems to vanish when the subject is distracted; 4)
focal disturbances, such as hypostenia or sensorial deficit,
without anatomic distribution; 5) a patient's hyper-reac-
tion during clinical examination.
Since the accurate evaluation of pain is controversial and
possibly influenced by a large number of factors, it might
be useful to introduce the concept of "behavior in pathol-
ogy" [30,49], which could include considerations such as
the perception of pain, any decision regarding treatment
and the person responsible for this decision, the meaning
of pain for the patient and the way the patient talks about
the pain and its effect on his/her functioning. The cultural
background, the socio-economical conditions, the psy-
chological functioning, the experiences, memory and
learning are some of the factors which may influence
behavior in pathology. Although the concept of behavior
in pathology has been applied more frequently to chronic
pain, several observations indicate that some of these fac-
tors play a significant role also in acute pain. In a pioneer-
ing study, Beecher [50] observed that soldiers who were
very severely wounded in battle often did not refer to pain
or if they did, it was often to a much lesser extent than
might have been expected, given the severity of the wound
in question. The author hypothesized that this might
reflect the relief of soldiers who had realized that now that
they were wounded they would be removed from the field
of battle and that their life would no longer be at risk; on
the other hand, life stressors might contribute to the
development of chronic pain [51].
It has also been demonstrated that a person's knowledge
and expectation of potential pain can modify his/her
response. Egbert and co-workers [52] found that the pre-
operatory psychological preparation of the patient had a
significant influence on post-surgical recovery as well as
the amount of pain felt. Other studies indicated the exist-
ence of significant differences between cultures and ethnic
groups with regard to how persons report pain and their
response to it. In pathology, the kind of behavior which is
generally considered acceptable varies from culture to cul-
ture. Zborowski [53] studied experiences of pain amongst
"old-Americans" (i.e. of Anglo-Saxon origin), Italo-Amer-
icans and American Jews and he observed that the "old-
Americans" were generally stronger and had a greater ten-
dency to avoid social contact when experiencing pain,
compared with the others. Similarly, Sternbach and Tur-
sky [54] compared different ethnic groups and found that
there were differences in the tolerance of pain between the
groups and this was subsequently reported also by other
authors [55-57].
Psychiatric comorbidity
Although there is unquestionably some connection
between pain and various psychiatric disorders, its exact
nature is a matter of debate. The majority of studies on
this topic have focused on the frequency of psychiatric dis-
orders amongst patients reporting pain, but a few studies
investigating pain in psychiatric subjects have reported
this as a common problem. Deplaine and coauthors [58]
found that 38% of 227 psychiatric inpatients reported
pain; Chaturvedi [59] identified pain symptoms in 18%
of patients in a psychiatric department. Both studies
underlined that pain was more frequent amongst patients
affected by neurosis, as compared with those suffering
from schizophrenia or psychotic disorders. Chronic pain
would seem to be associated most frequently with a vari-
ety of depressive disorders such as major depression, dys-
thymia and adaptation disorder with depressive mood.
The available literature reports a variability in the preva-
lence of chronic pain ranging from 10 to 100% [60,61].
The heterogeneous results may reflect the difficulty in
applying this diagnosis to patients with pain, but may also
be related to differences in the evaluated populations.
These disorders have been identified in patients with an
evident organic etiology for pain as well as in subjects
without it, although the disorders would seem to be more
common in the latter group [62].Page 4 of 11
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oping pain as a response to depressive symptoms, other
viewpoints have been put forward. According to Engel
[63], there may be individuals who, as a result of specific
psychological factors, may be considered "prone to pain".
Similarly, Blumer and Heilbronn [64] hypothesized that
associated mental disorders might precede and/or create a
predisposition towards pain and they described an indi-
vidual prone to pain, for whom it represents a form of
masked depression. Some studies indicate that depressive
disorders and alcohol dependence are more common in
first-degree relatives of patients with chronic pain, thus
suggesting a possible environmental or biological predis-
position to the development of pain [32,62,65-67]. Other
studies would suggest that depression is secondary to pain
[31,68], or that both problems can coexist independently
or as a result of a common psychological or neurochemi-
cal background [62,69,70].
Even some forms of acute pain appear to be associated fre-
quently with other mental disorders; Beithman and co-
authors [71] observed that more than 30% of patients
with chest pain and normal coronary circulation assessed
by means of coronarography met the criteria for panic dis-
order.
Depression
The National Health and Nutrition Study underlined that
depression was more frequent in older patients, irrespec-
tive of the presence of any pain [72]; nevertheless, the rela-
tionship between pain and depression is still controversial
[73]. Approximately 60% of patients with depression
present pain at the moment of the diagnosis [74,75]. The
presence of depressive disorder may increase the risk of
developing a musculoskeletal pain, headache and chest
pain 3 years later on [12,76-78]. Elderly patients with
depression are at increased risk for cervical, lumbar and
hip pain. Even after 8 years, patients with a previous
depression still had a double risk of developing chronic
pain, as compared with non-depressed patients.
Depression prevalence was 12% in individuals with three
or more pain-related symptoms, as compared with 1% of
patients without pain or one only pain-related symptom,
amongst 1016 subjects [79]. Major depression prevalence
in patients with chronic lumbar pain was three times
higher than in the general population [80]. In groups of
patients with symptoms with no medical explanation,
such as lumbar pain or dizziness, two thirds had a history
of recurrent major depression compared with less than
20% in the control group with medical disorders
[31,81,82]. In patients with chronic pain included in a
program of pain evaluation, between 8% and 50% had
suffered from major depression [83]. Where pain led to a
loss of independence or motricity with impairment of
social functioning, the risk of depression increased signif-
icantly [84]. Individuals with chronic problems are at a
higher risk of developing lifetime depression and it has-
been hypothesized that this may be the case with particu-
larly vulnerable individuals.
Depression is not simply a comorbid condition when
associated with chronic pain, since it interacts by increas-
ing morbility and mortality. Patients with chronic pain
and depression have reported major pain, a reduction in
control over life events and a higher probability of coping
with stress by adopting passive strategies [74]. They have
reported also that this interfered with their lives and they
exhibited pain-related behaviors more frequently than did
those patients with chronic pain but without depression
[85,86]. The presence of pre-operatory depression in
patients who underwent lumbar disc surgery was a predic-
tor of a worse result during a 1-year follow-up [87]. In
patients with rheumatoid arthritis, depressive symptoms
were significantly associated with negative functional
results and with a greater utilization of health services
[88]. Depression may be a significant predicting factor of
pain persistence and of anticipated retirement [12,89].
However, the measurement of pain threshold, by means
of different techniques, has led to controversial findings
[73].
Patients with headache, chronic abdominal pain and
painful orthopaedic syndromes have reported a higher
level of suicide thoughts and attempts than those without
[90]. In those patients reporting a suicide attempt, 25%
suffered from a somatic disease and 21% took pain reliev-
ers daily for the pain [91]. Patients with chronic pain are
at two to three times greater risk of a completed suicide
than the general population [92]. Oncological patients
with pain and depression showed a higher likelihood of
committing suicide, by searching for information regard-
ing the possibility of suicide or withdrawal from treat-
ment; however, if affected by pain but without
depression, they did not request euthanasia or assisted
suicide [93], therefore depression must be treated cor-
rectly and not simply "understood" as the unavoidable
result of chronic pain.
Anxiety
Patients with different painful syndromes, such as chronic
lumbar pain, chronic cervical pain following whiplash or
chronic pain due to prostatic cancer, showed an increased
risk of anxiety syndromes or disorders [94-97]. At least
50% of patients show anxiety symptoms and 19% have an
anxiety disorder such as panic disorder or generalized anx-
iety disorder [32,98,99].
A prospective study involving 1007 young adults found
that a history of headache was associated with a higherPage 5 of 11
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other hand, anxiety disorders are associated with high
somatic preoccupation levels and physical symptoms. In
a study of patients with panic disorder, at least 40%
described chronic pain symptoms and more than 7% took
pain relievers daily [101]. When compared with other
patients with panic disorder, this sub-group had a higher
frequency of abnormal behaviors related to the disease.
The self-evaluation of pain intensity in patients with rheu-
matoid arthritis was significantly influenced by the pres-
ence of anxiety and depression, even when the factor
related to the activity of the main disease was controlled
[102].
Substance use
Terms such as addiction, misuse, excessive use and abuse
are usually applied inconsistently to describe different
behaviors and they may complicate the interpretation of
several studies. Frequently the use of drugs is not reported
completely and this impairs the accurate evaluation of
their use when made by patients with chronic pain [103];
in patients with chronic pain who develop an addiction to
new substances, usually this derives from drugs prescribed
by the physician [104,105]. The mechanism underlying
the relapse of substance abuse amongst these patients is
not well-known and it is based upon several factors; how-
ever, a period of pain followed by a remission after the use
of drugs constitutes a typical example of a situation likely
to lead to their use in the future [106]. In a study per-
formed in a group of outpatients consulting a centre spe-
cialized in the treatment of pain, almost 90% were taking
drugs [107], opioids were prescribed in 70% of the cases,
while antidepressants and benzodiazepines were taken by
25% and 18% of the patients, respectively. Amongst this
population, 8% met DSM-III-R criteria for substance
abuse or addiction; however, misuse and drug abuse were
not limited to psychoactive substances. In a review of 24
studies on drug and alcohol dependence in patients with
chronic pain, only 7 met the standard criteria for sub-
stance abuse disorders, and the prevalence ranged from
3.2% to 18.9% [108]. In a study carried out in patients
with chronic lumbar pain, 34% had a substance abuse dis-
order, which in all cases had already been present before
the onset of pain [94]. Individuals with a history of sub-
stance abuse ran a major risk of resuming substance abuse
while suffering from chronic pain, and also of suffering
further physical damage [109].
Research related to substance abuse has revealed abnor-
malities in the perception and tolerance of pain. In a study
carried out in patients with cocaine and opioid abuse, tol-
erance of the cold pressor test was significantly lower
amongst those who were still indulging in substance
abuse, than amongst those who were no longer doing so
[110]. Alcoholic patients and non-alcoholic males with a
high genetic risk of alcoholism, have a higher sensitivity
than control subjects to painful stimuli, but this difference
in sensitivity was reduced by the intake of pharmacologi-
cal doses of alcohol [111]. This increase in sensitivity and
the relief due to substance abuse would suggest a possible
explanation of substance abuse in patients with chronic
pain.
Pharmacological Treatments
This review will focus mainly on pharmacological strate-
gies with special attention being paid to the use of psycho-
tropic compounds. However, apart from pharmacological
agents, there exist several heterogeneous techniques for
the treatment of pain, such as surgical intervention, nerve
blocking, physiotherapy, acupuncture or electrical stimu-
lation, just to mention a few. Among psychotherapies,
moreover, cognitive-behavioral therapies (CBT) are con-
sidered effective treatments for a variety of pain problems
[112-114]. A discussion of these techniques would go
beyond the scope of this paper and could be found else-
where [115].
Opiates
The use of opiates for non-malignant chronic pain is a
matter of debate [116]. For a long time, opiates were
reserved for the treatment of painful syndromes related to
cancer or to those of acute pain; however, different studies
aimed at assessing the risk of abuse have provided reassur-
ing results, in particular that carried out in a group of
more than 12000 patients with medical disorders who
had been treated with opiates, which showed that, of
those without a past history of abuse, only 4 developed
drug dependence [117,118]. Open-label and controlled
trials support the safety and the efficacy of opiates in the
treatment of non-malignant chronic pain.
The most common side-effect following chronic use is the
reduction of gastro-intestinal motility, with consequent
constipation [119]. However, the main reason why these
drugs are not widely prescribed is that there is concern
regarding possible cognitive impairment. Such literature
as is available has reviewed only some of the effects shown
by neuro-psychological tests or electroncephalogram
modifications in patients taking combinations of drugs,
mainly sedatives and hypnotics [120-123]. When the opi-
ate treatment is not effective, the drug should be sus-
pended gradually in order to decrease withdrawal
symptoms. The opiate withdrawal is usually dangerous
only in those patients at risk with regard to an increase in
the sympathetic tone, that is, for instance, in those who
show an increase in intracranial pressure or unstable
angina. In any event, however, it should be borne in mind
that opiate reduction usually leads to a return of the orig-
inal painful symptoms (rebound pain).Page 6 of 11
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After the first study reporting the effectiveness of imi-
pramine in the treatment of trigeminal neuralgia [124],
antidepressants, especially tricyclics (TCAs), have fre-
quently been prescribed for the treatment of several
chronic painful syndromes, but mainly for neuropathic
pain. Various different studies have suggested that the
antidepressant effects on pain are mediated by the block-
ade of the norepinephrine and serotonin re-uptake which
increases neurotransmitter levels and, therefore, potenti-
ates the activation of the descendent inhibitory pathways
[62,125]. Other aspects of monoaminergic systems are
involved in the analgesic action of antidepressants, for
example, β-adrenergic receptors may mediate the analge-
sic effects of desipramine and nortriptyline [126]. In gen-
eral, amitriptyline, or TCAs with a similar
pharmacological profile, are considered the most effective
drugs; however, randomized controlled clinical trials have
not demonstrated the existence of any significant differ-
ences between TCAs [127]. In a review of 39 controlled
studies versus placebo, in 80% of the cases, antidepres-
sants proved superior to the placebo [128]. TCAs have
been the most effective drugs for pain remission in neuro-
pathic pain and headache, and the analgesic activity
would seem to be independent of any effect on mood
[129-134]. A recent controlled randomized study of
nortriptyline versus placebo in patients with chronic lum-
bar pain without depression, showed a significant reduc-
tion in the scores related to pain intensity [135]. The
results of studies which have assessed the plasma levels of
drugs necessary for pain remission are still controversial
and clear guidelines have not been established as yet
[136]. Nortriptyline, the main amitriptyline metabolite,
induces less sedation and less orthostatic hypotension
than imipramine, but has an analgesic potency compara-
ble to that of amitriptyline [137,138]. The cost of pain
treatment with TCAs is usually much lower than that with
other antidepressants or drugs with an analgesic action,
such as β-blockers or calcium-antagonists [139]. Selective
serotonin re-uptake inhibitors (SSRIs) have a weak anti-
nociceptive action in animal models of acute pain [140-
142]. Several studies have investigated the role of different
serotonin receptor subtypes in the mechanisms of pain,
but they are very controversial [143-145]. SSRIs do not
seem to be as effective as TCAs for chronic pain; for
instance, desipramine is superior to fluoxetine in the treat-
ment of painful peripheral diabetic neuropathia [146].
Recently these drugs have been shown to be effective and
well-tolerated in the treatment of headache, in particular
of migraine [147,148]. The role of biogenic amine in the
descendent inhibition of pain would suggest the potential
efficacy of all antidepressants, whatever their mechanism
of action [149]. In studies of thermic nociception, the
norepinephrine re-uptake inhibitors, such as reboxetine,
and the dopamine re-uptake inhibitors, such as bupro-
pion, may produce an antinociceptive effect [150]. Trazo-
done has been effective in reducing pain in a double-blind
controlled study carried out in patients with chronic lum-
bar pain [151,152]. In an animal model of neuropathic
pain, venlafaxine, a compound inhibiting both the re-
uptake of norepinephrine and serotonin (SNRI), was
shown to prevent the development of hyperalgesia [152].
Of note, duloxetine, a balanced SNRI, has been recently
considered a new treatment option for patients with neu-
ropathic pain after showing promising results in control-
led trials [153].
Anticonvulsants
Anticonvulsants are considered the most effective drugs in
the treatment of trigeminal neuralgia, of diabetic neurop-
athy, and of migraine recurrence [137]. Phentoine was the
first drug found to be effective in the treatment of trigem-
inal neuralgia in 1942 [154]. Carbamazepine is the most
studied anticonvulsant which has proven to be effective in
the treatment of neuropathic pain [155]. However, anti-
convulsants have different pharmacological actions which
may have a role in analgesia with potentially useful con-
nections with a series of chronic pain syndromes. Several
anticonvulsants block the activity of sodium channels
and, therefore, would stabilize the pre-synaptic neuronal
membrane, decrease the release of excitatory neurotrans-
mitters and reduce the spontaneous firing of damaged or
recovering nociceptive fibres. Phentoine regulates many
aspects of nervous functioning, such as the activity of
ATPase, synaptic transmission, the release of neurotrans-
mitters and ion conduction [156]. Carbamazepine
reduces the tryptophan concentration binding plasma
proteins and consequently increases serotonin levels in rat
brain [157]. The use of carbamazepine, however, is
restricted by unwanted side-effects such as sedation, ataxia
and plastic anemia. Therapeutic plasma levels have not
been defined clearly, but there is evidence to suggest that
low levels may be effective in reducing pain [158].
New classes of anticonvulsants have different pharmaco-
logical actions which may prove to be analgesic. Valproic
acid is more frequently used in migraine prophylaxis but
it is effective also in the treatment of neuropathic pain
[159]. In a study on migraine, valproate proved to be
effective in the prophylactic treatment of more than two
thirds of the patients, with minimal side-effects such as
nausea, dizziness or tremors [160]. The mechanism of
action of valproate is probably related to an increase in
GABA levels, mediated by the inhibition of GABA
transaminase and the increase of GABA synthesis. Val-
proate is usually well-tolerated, but it requires regular
monitoring because of its potential hepatotoxicity and
suppression of bone marrow.Page 7 of 11
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reduce pain in multiple sclerosis, migraine, post-herpetic
neuralgia (PHN) and reflex sympathetic distrophy
[161,162]. The mechanism of action of gabapentin may
be related to the binding to the α2δ subunit of the voltage-
dependent calcium channels [163]. Clinical cases exist
which suggest that lamotrigine may be effective in reduc-
ing phantom limb pain, post-stroke central pain and PHN
[164,165]. The mechanism of action of lamotrigine may
result from the reduction in the long-term excitatory
effects of glutamatergic nociceptive transmission medi-
ated by NMDA receptors, but it also blocks the voltage-
dependent sodium channels [166-168].
Benzodiazepines
Benzodiazepines are frequently prescribed for insomnia
and anxiety in patients with chronic pain [169,170]. In a
review of published literature, only a few conditions
involving chronic pain, such as trigeminal neuralgia, ten-
sive headache and temporal-mandible joint disorder,
seem to improve after treatment with benzodiazepines
[171]. It is difficult to assess the positive effects of benzo-
diazepines, however the negative effects have been stud-
ied thoroughly and they amount to more than the usual
worries related to abuse, dependence, abstinence or sec-
ondary effects on mood. Elderly subjects are particularly
sensitive to the side-effects of benzodiazepines, such as
sedation [172-176]. Benzodiazepines determine also a
cognitive impairment, as demonstrated by the abnormal-
ities of neuropsychological tests and electroencephalo-
grams [120].
Conclusion
Pain is a common problem in medical practice and it con-
tinues to be underestimated and undertreated despite the
existence of effective treatments.
The psychological aspects of pain are evident; nevertheless
these are rarely assessed or managed as they should be.
Furthermore, pain can often represent a non-specific sign
or symptom of specific psychiatric disorders, such as
depression or anxiety, or it can constitute a disorder in
itself, as acknowledged by current psychiatric classifica-
tion systems and as a result, in most cases, psychiatric
intervention can prove beneficial.
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